Contineum Therapeutics, Inc.

CTNM

Contineum Therapeutics, Inc.

CTNM

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2026-06-01Shares Purchased (TTM):0Shares Sold (TTM):47,447

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:30,465,303Shares Outstanding:37,339,026Institutional Ownership Pct.:81.59%

Earnings Market Reaction:

Filing Date:2026-07-30Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31
Common Class A	0	33	0	-	-19	19	0	-	-	-
Common Class B	0	5	0	-	0	7	0	-	-	-
Assets
Cash And Cash Equivalents At Carrying Value	15	20	76	43	21	22	22	41	77	16
Assets Current
Assets Current	243	253	268	185	177	192	206	215	220	120
Marketable Securities Current	222	226	187	140	155	168	183	173	141	102
Prepaid Expense And Other Assets Current	6	7	5	3	1	1	2	1	2	2
Property Plant And Equipment Net	1	1	1	1	1	1	1	1	1	1
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	3
Operating Lease Right Of Use Asset	6	7	2	5	5	5	5	6	0	0
Assets	250	261	277	191	183	198	213	216	221	124
Liabilities And Stockhold…
Other Liabilities Noncurrent	-	-	-	-	-	-	0	0	0	0
Accounts Payable Current	1	1	1	1	2	4	2	1	1	1
Liabilities Current
Liabilities Current	7	7	10	6	7	9	10	6	4	6
Accrued Liabilities Current	4	3	6	4	4	4	7	4	3	5
Operating Lease Liability Current	2	2	2	1	1	1	1	1	0	0
Operating Lease Liability Noncurrent	4	5	6	4	4	5	5	0	0	0
Temporary Equity Carrying Amount Attributable To P…	-	-	-	-	-	-	0	0	0	193
Common Stock Value	-	-	-	-	-	-	-	-	-	0
Liabilities	11	11	16	10	11	13	15	6	4	7
Preferred Stock Value	0	0	0	0	0	0	0	0	0	-
Additional Paid In Capital	447	442	438	342	321	318	315	312	310	8
Stockholders Equity
Stockholders Equity	240	250	261	180	171	185	198	210	218	-76
Retained Earnings Accumulated Deficit	-207	-192	-177	-162	-149	-133	-117	-103	-93	-84
Accumulated Other Comprehensive Income Loss Net Of…	-1	-0	0	0	0	0	0	1	-0	-0
Temporary Equity Par Or Stated Value Per Share	-	-	-	-	-	-	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	-	-	-	-	-	-	-	-	-	220
Temporary Equity Shares Authorized	-	-	-	-	-	-	0	0	0	17
Liabilities And Stockholders Equity	250	261	277	191	183	198	213	216	221	124
Temporary Equity Shares Issued	-	-	-	-	-	-	0	0	0	16
Temporary Equity Shares Outstanding	-	-	-	-	-	-	0	0	0	16
Temporary Equity Liquidation Preference	-	-	-	-	-	-	-	-	-	0
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	-
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10
Common Stock Par Or Stated Value Per Share	-	-	-	-	-	-	-	-	-	0.001
Common Stock Shares Issued	-	-	-	-	-	-	-	-	-	2
Shares Outstanding	-	-	-	-	-	-	-	-	-	2
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	-
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	-

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-6.25%	-1.39%	-2.29%	-	-	-	-	-	-	-	-	-
2025	23.70%	1.04%	55.21%	74.17%	98.67%	84.17%	3.84%	11.39%	11.39%	-3.40%	-10.14%	0.36%
2024	9.02%	33.89%	25.40%	-3.65%	-1.62%	-3.65%	-13.52%	-16.47%	-35.15%	9.78%	-31.52%	-44.64%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31
Liquidity Ratios
Current Ratio	37.17	38.00	27.50	29.07	24.51	21.47	20.69	37.06	58.92	19.20
Quick Ratio	36.25	37.00	26.98	28.68	24.33	21.31	20.53	36.84	58.48	18.91
Working Capital	236.05M	246.31M	258.17M	178.57M	169.63M	183.19M	196.41M	209.34M	216.58M	113.48M
Leverage & Debt
Debt to Equity	0.04	0.05	0.06	0.06	0.07	0.07	0.07	0.03	0.02	-0.09
Debt Ratio	0.04	0.04	0.06	0.05	0.06	0.07	0.07	0.03	0.02	0.05
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-
Per Share Metrics
Diluted EPS TTM	-1.54	-1.57	-2.17	-	-2.20	-1.93	-2.18	-	-	-
Free Cash Flow Per Share TTM	-1.43	-1.54	-2.01	-1.88	-1.81	-1.53	-1.72	-	-	-
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-
Growth Metrics
Net Income Growth (1Y)	1.22%	17.28%	41.93%	-	-	-	-	-	-	-
EPS Growth (1Y)	-30.04%	-18.74%	-0.84%	-	-	-	-	-	-	-
Valuation Metrics
P/E TTM	-10.67	-8.34	-5.28	-5.56	-1.81	-3.62	-6.71	-	-	-
P/B TTM	2.56	1.95	1.21	1.83	0.60	0.98	1.43	2.34	1.89	-
Market Cap	614.10M	487.65M	316.62M	330.36M	102.81M	180.57M	283.52M	492.47M	411.29M	-
Enterprise Value	599.39M	467.49M	241.02M	287.72M	82.02M	158.10M	261.58M	451.58M	334.06M	-
Calculated Values
Free Cash Flow TTM	-53.46M	-57.66M	-55.54M	-52.83M	-46.78M	-39.70M	-33.36M	-	-	-
Net Debt	-14.71M	-20.16M	-75.60M	-42.63M	-20.78M	-22.47M	-21.94M	-40.89M	-77.23M	-16.26M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-01Sale

Owner: Lorrain, Daniel S.

Title: Chief Scientific Officer

Shares: 4,170

Price/Share: $13.16

Value: $54,877.20

Shares Owned: 139,372

Relationship: Officer

Ownership: Direct

2026-05-01Sale

Owner: Lorrain, Daniel S.

Title: Chief Scientific Officer

Shares: 4,170

Price/Share: $13.45

Value: $56,086.50

Shares Owned: 143,542

Relationship: Officer

Ownership: Direct

2026-04-06Sale

Owner: Lorrain, Daniel S.

Title: Chief Scientific Officer

Shares: 4,170

Price/Share: $13.43

Value: $56,003.10

Shares Owned: 147,712

Relationship: Officer

Ownership: Direct

2026-03-02Sale

Owner: Watkins, Tim

Title: CMO & Head of Development

Shares: 3,611

Price/Share: $15.02

Value: $54,237.22

Shares Owned: -

Relationship: Officer

Ownership: Direct

2026-03-02Sale

Owner: Lorrain, Daniel S.

Title: Chief Scientific Officer

Shares: 4,170

Price/Share: $15.01

Value: $62,591.70

Shares Owned: 151,882

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-01	Lorrain, Daniel S.	Officer	Chief Scientific Officer	Direct	Sale	4,170	13.16	$54,877.20	139,372	4
2026-05-01	Lorrain, Daniel S.	Officer	Chief Scientific Officer	Direct	Sale	4,170	13.45	$56,086.50	143,542	4
2026-04-06	Lorrain, Daniel S.	Officer	Chief Scientific Officer	Direct	Sale	4,170	13.43	$56,003.10	147,712	4
2026-03-02	Watkins, Tim	Officer	CMO & Head of Development	Direct	Sale	3,611	15.02	$54,237.22	0	4
2026-03-02	Lorrain, Daniel S.	Officer	Chief Scientific Officer	Direct	Sale	4,170	15.01	$62,591.70	151,882	4
2026-02-25	Lorrain, Daniel S.	Officer	Chief Scientific Officer	Direct	Sale	3,824	16.01	$61,222.24	156,052	4
2026-02-25	Stengone, Carmine N.	Director,Officer	CEO and President	Direct	Sale	2,700	16.02	$43,254.00	14,954	4
2026-02-19	Lorrain, Daniel S.	Officer	Chief Scientific Officer	Direct	Sale	100	16.00	$1,600.00	156,052	4
2026-02-11	Lorrain, Daniel S.	Officer	Chief Scientific Officer	Direct	Sale	400	16.00	$6,400.00	156,052	4
2026-02-11	Stengone, Carmine N.	Director,Officer	CEO and President	Direct	Sale	400	16.00	$6,400.00	14,954	4
2026-02-03	Lorrain, Daniel S.	Officer	Chief Scientific Officer	Direct	Sale	4,170	15.04	$62,716.80	156,052	4
2026-01-28	Watkins, Tim	Officer	CMO & Head of Development	Direct	Sale	3,611	14.28	$51,565.08	0	4
2026-01-05	Lorrain, Daniel S.	Officer	Chief Scientific Officer	Direct	Sale	4,170	10.74	$44,785.80	160,222	4
2025-12-29	Watkins, Tim	Officer	CMO & Head of Development	Direct	Sale	3,611	12.06	$43,548.66	0	4
2025-12-23	Lorrain, Daniel S.	Officer	Chief Scientific Officer	Direct	Sale	4,170	12.23	$50,999.10	164,392	4
2024-11-25	Lorrain, Daniel S.	Officer	Chief Scientific Officer	Direct	Sale	1,010	16.02	$16,180.20	168,562	4
2024-11-18	Lorrain, Daniel S.	Officer	Chief Scientific Officer	Direct	Sale	6,190	16.71	$103,434.90	169,572	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

81.59%

Inst. Shares: 30,465,303

Shares Outstanding: 37,339,026

2025-12-31

106.49%

Inst. Shares: 29,498,022

Shares Outstanding: 27,700,855

2025-09-30

62.06%

Inst. Shares: 17,449,494

Shares Outstanding: 28,115,548

2025-06-30

53.47%

Inst. Shares: 13,845,404

Shares Outstanding: 25,895,996

2025-03-31

58.40%

Inst. Shares: 15,108,633

Shares Outstanding: 25,868,935

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	30,465,303	37,339,026	81.59%
2025-12-31	29,498,022	27,700,855	106.49%
2025-09-30	17,449,494	28,115,548	62.06%
2025-06-30	13,845,404	25,895,996	53.47%
2025-03-31	15,108,633	25,868,935	58.40%
2024-12-31	15,764,914	19,352,859	81.46%
2024-09-30	13,577,087	25,730,014	52.77%
2024-06-30	12,341,826	23,355,588	52.84%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Contineum Therapeutics, Inc. (CTNM) — SEC Financial Statements & Analysis

Contineum Therapeutics, Inc. (CTNM) is a pharmaceutical preparations company, incorporated in DE. Contineum Therapeutics, Inc. trades on Nasdaq as: CTNM. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Contineum Therapeutics, Inc. reported a Debt-to-Equity ratio of 0.04x, a Price-to-Book (P/B) ratio of 2.56x (TTM), at a market cap of $614.10M. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 0.04x
P/B TTM: 2.56x
Market Cap: $614.10M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Contineum Therapeutics, Inc. in?

Contineum Therapeutics, Inc. (CTNM) operates in the Pharmaceutical Preparations industry.

What is CTNM's market cap?

Contineum Therapeutics, Inc. (CTNM) has a market capitalization of $614.10M as of 2026-06-30.

What exchange does CTNM trade on?

Contineum Therapeutics, Inc. (CTNM) trades on the Nasdaq.

Where is Contineum Therapeutics, Inc. incorporated?

Contineum Therapeutics, Inc. is incorporated in DE.